Ibrutinib followed by ofatumumab consolidation in previously untreated patients with chronic lymphocytic leukemia (CLL): GELLC-7 trial from the Spanish group of CLL (GELLC)

Authors

Pau Abrisqueta

Published

May 25, 2024

Abstract

BTK inhibitors have been concurrently administered with anti-CD20 monoclonal antibodies (mAbs) in chronic lymphocytic leukemia (CLL). However, the optimal regimen for combining these two drugs remains pending.

Supporters

Support the authors with ResearchCoin

Journal

EClinicalMedicine

Topics

DOI

10.1016/j.eclinm.2024.102642

Ibrutinib followed by ofatumumab consolidation in previously untreated patients with chronic lymphocytic leukemia (CLL): GELLC-7 trial from the Spanish group of CLL (GELLC)

Authors

Pau Abrisqueta

Published

May 25, 2024

Abstract

Supporters

Support the authors with ResearchCoin

Journal

EClinicalMedicine

Topics

DOI

10.1016/j.eclinm.2024.102642

Paper

Paper

Paper

Paper

Ibrutinib followed by ofatumumab consolidation in previously untreated patients with chronic lymphocytic leukemia (CLL): GELLC-7 trial from the Spanish group of CLL (GELLC)

Abstract

Supporters

Journal

Topics

DOI

Ibrutinib followed by ofatumumab consolidation in previously untreated patients with chronic lymphocytic leukemia (CLL): GELLC-7 trial from the Spanish group of CLL (GELLC)

Abstract

Supporters

Journal

Topics

DOI